Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CNP-106 by Cour Pharmaceuticals Development for Myasthenia Gravis: Likelihood of Approval
CNP-106 is under clinical development by Cour Pharmaceuticals Development and currently in Phase II for Myasthenia Gravis. According to GlobalData,...